NCCN 2023 Nursing Program: Advancing Oncology Nursing™

March 30, 2023

This program will provide oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Presentations will focus on a current and critical issues to provide oncology nurses with practical information that can be implemented in the practice setting.

Target Audience

This program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

Overall Learning Objectives
•   Evaluate the advances in the management of patients with cancer and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care. 
•   Review issues related to Providing Access to Cancer Care in Historically Marginalized Communities: Lessons Learned from Dana-Farber’s Cancer Care Equity Program; Operational Excellence for Inpatient Rounding; Early Involvement of Palliative Care in Cancer Treatment; New Challenges in the Management of Pulmonary Toxicities; Management of Acute Hyperglycemia; Updates in Biomarker Testing in Non-Small Cell Lung Cancer; and Harm Reduction Strategies for Substance Use in Patients with Cancer.

Providing Access to Cancer Care in Historically Marginalized Communities: Lessons Learned from Dana-Farber’s Cancer Care Equity Program
•   Examine disparities in cancer morbidity in historically marginalized communities.
•   Describe the importance of trust between specialty providers and primary care providers in creating access to cancer care.
•   Describe patient navigation initiatives to mitigate disparities and open access to cancer care for historically marginalized patients.

Operational Excellence for Inpatient Rounding
•   Discuss the importance of engaged employees and the ramifications on quality of care, cost, and patient satisfaction.
•   Describe how patient rounding could be used to achieve operational excellence.
•   Review how data may be collected and shared to constantly evolve quality initiatives. 

Early Involvement of Palliative Care in Cancer Treatment
•   Discuss the importance of early referral to a multidisciplinary palliative care team.
•   Explain the role of the nurse/advanced practice provider in palliative care.
•   Describe how patients and health care systems can benefit from early palliative care.

New Challenges in the Management of Pulmonary Toxicities
•   Describe the incidence and impact of pulmonary toxicities in cancer treatment.
•   Identify the cancer therapies that contribute to the development of pulmonary toxicities.
•   Explain management strategies to prevent and mitigate pulmonary toxicities. 

Management of Acute Hyperglycemia
•   Define hyperglycemia and potential negative outcomes associated with it.
•   Describe the relationships between malignancy, chemotherapeutic agents, and hyperglycemia.
•   List appropriate regimens for ambulatory treatment of acute hyperglycemia in patients with cancer.

Updates in Biomarker Testing in Non-Small Cell Lung Cancer
•   Discuss the importance of comprehensive/timely testing for targetable biomarkers in non-small cell lung cancer (NSCLC).
•   Discuss the possible barriers to biomarker testing and what to do with inconclusive results.
•   Identify targetable biomarkers in NSCLC and drugs used to treat those mutations.

Harm Reduction Strategies for Substance Use in Patients with Cancer
•   Describe the incidence and risks of substance use in patients living with cancer.
•   Discuss the biology of addiction.
•   Explain principles of harm reduction as they relate to substance use and how they can be applied to nursing practice.

Additional information
Supporters: 

This activity is supported by educational grants from:

  • Genentech, a member of the Roche Group
  • Novartis
  • Seagen 

This activity is supported by independent educational grants from:

  • Incyte Corporation
  • Merck & Co., Inc.

This activity is supported by an independent medical educational grant from:

  • ADC Therapeutics

This activity is supported by a grant from:

  • Pfizer Inc.
Course summary
Available credit: 
  • 5.25 ANCC contact hours
    • 1.50 ANCC Pharmacology Contact Hours
  • 5.25 Participation
Course opens: 
03/29/2023
Course expires: 
10/31/2023
Event starts: 
03/30/2023 - 8:00am EDT
Event ends: 
03/30/2023 - 3:00pm EDT
Cost:
$0.00
Add to calendar: 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions 

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Christopher Acebedo, DNP, MS, RN, ACNP-BC 
Jessica Cerulli, DNP, FNP-C, RN 
Rachael Fornwalt, AG-ACNP 
Kristina M. Gregory, RN, MSN, OCN 
Carey Ramirez, ANP-C, ACHPN 
Ludmila Svoboda, RN, BSN, MA, OCN

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Gretchen McNally, PhD, ANP-BC, AOCNP
JADPRO Insight Forum: Honoraria
Novartis Pharmaceuticals Corporation: Grant/Research Support 

Zoe Quandt, MD
Novartis Pharmaceuticals Corporation: Scientific Advisor 

Beth Sandy, MSN, CRNP 
Amgen Inc.: Product/Speakers Bureau 
AstraZeneca Pharmaceuticals LP: Product/Speakers Bureau
Eli Lilly and Company: Honoraria
Janssen Pharmaceutica Products, LP: Consulting Fee
Jazz Pharmaceuticals Inc.: Product/Speakers Bureau
Merck & Co., Inc.: Product/Speakers Bureau
Takeda Pharmaceuticals North America, Inc.: Product/Speakers Bureau

NCCN Staff Disclosures 

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 5.25 contact hours.

This program offers 1.5 pharmacotherapeutic contact hours for nurses. Eligible sessions are: 

  • Early Involvement of Palliative Care in Cancer Treatment
  • New Challenges in the Management of Pulmonary Toxicities
  • Management of Acute Hyperglycemia

Available Credit

  • 5.25 ANCC contact hours
    • 1.50 ANCC Pharmacology Contact Hours
  • 5.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to start the credit claiming process.
You must be logged in with the same email address used for program registration.

CE credit should be claimed for the program as a whole, not session by session. You may claim credit for the program only one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording. (Please note that you have access to all of the session recordings for 60 days following the live program.) 

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing